Articles tagged with Drug Therapy
Adding camrelizumab to neoadjuvant chemotherapy significantly improved pathological complete response in patients with early or locally advanced triple-negative breast cancer. The treatment showed substantial benefits, leading researchers to explore its potential as a neoadjuvant strategy.
The University of Surrey's research focuses on targeting mutated pathways with new drugs to treat rare conditions like immunodeficiencies. The team discovered that mTOR inhibitors can help restore normal B cell function.
A new study reveals significant provincial and territorial variations in reimbursement criteria for cardiovascular medications in Canada. The current system leads to unequal access to evidence-based treatments, with the most vulnerable groups facing restricted access to life-saving medications.
Researchers at TUM have grown tumor organoids that reproduce the morphological complexity of pancreatic cancer cells in the laboratory. The team used machine learning to categorize the organoids into different phenotypes based on their appearance and behavior, which react differently to treatments.
Researchers have developed an mRNA cure for pre-eclampsia using a lipid nanoparticle, reducing maternal blood pressure and improving fetal health. The therapy, tested in pregnant mice, has shown promising results and is poised to move forward to human trials.
Researchers at Chung-Ang University have identified a crucial role for specific tRNA fragments in cancer progression, revealing their ability to regulate gene expression and influence tumor growth. The study suggests that these fragments could serve as biomarkers for early-stage cancer detection and targets for therapeutic interventions.
The PROSPECT-Lung trial evaluates the role of immunotherapy before and after surgery in resectable non-small cell lung cancer patients. The trial aims to determine whether adding immune checkpoint inhibitors to standard chemotherapy improves survival outcomes.
Lauren Averett Byers, a professor at MD Anderson Cancer Center, has received the 2025 Edith and Peter O'Donnell Award in Medicine from Texas Academy of Medicine, Engineering, Science and Technology (TAMEST) for her fundamental discoveries in small cell lung cancer. Her work has led to personalized treatments and improved patient outcomes.
Researchers have identified new potential therapeutic targets for diabetic kidney disease (DKD), a leading cause of kidney failure. The study reveals common and cell-type-specific changes caused by insulin-resistance, representing new targets for pharmacological or targeted gene therapy approaches.
Researchers found variation in practice patterns of sarcoidosis treatment, particularly in the use of nonsteroidal immunosuppressive medications and sequence of administration. The study highlights the need for future randomized trials and comparative effectiveness studies to ascertain optimal treatment algorithms.
The collaboration aims to evaluate the potential of AMB-066 as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease. MD Anderson researchers have identified a potential opportunity for AMB-066 to effectively treat MRD-positive CRC, based on robust preclinical data.
Researchers identified the critical role of TIMM50 protein in mitochondrial energy production and its link to a severe and rare neurological disease. The study's findings suggest potential targets for future drug treatments and advance research on protein import into mitochondria in brain cells.
Dr. Aditya Bardia's appointment as Editor-in-Chief of Breast Cancer Research and Treatment reflects his expertise in targeted therapies and innovative research. He aims to foster innovation and disseminate knowledge benefiting patients and the scientific community through this journal.
Dr. Christopher Seet has received a $2.9 million R37 MERIT Award from the National Cancer Institute to develop innovative T cell therapies for cancer. The grant will support research into iPSC-derived T cells, which can be engineered for enhanced tumor-fighting capabilities.
A study found that psilocybin-assisted psychotherapy significantly reduced depression among clinicians providing front-line COVID-19 care. The treatment was more effective than a placebo, with participants experiencing greater reductions in symptoms over time.
Pusan National University researchers have identified genes that are overexpressed in peri-implantitis, a condition similar to periodontitis but with higher recurrence rates. The study's findings may help diagnose and treat the disease with targeted therapies.
A new study found that gene therapy delandistrogene moxeparvovec significantly extended the median survival of Duchenne muscular dystrophy (DMD) rats to >25 months. Additionally, the treatment elicited statistically significant improvements in cardiac parameters and mobility.
Researchers have found that B7-H4 helps ACC tumors evade the immune system, leading to poor survival outcomes. A new drug targeting B7-H4 showed promising results in shrinking tumors in aggressive cases.
A new review synthesizes evidence from molecular studies, animal research, and human trials to understand how ayahuasca influences emotional processing and memory systems. Key findings include ayahuasca's dual action through serotonin receptor types 5-HT2A and 5-HT1A.
The landmark review charts the transformation of pituitary tumor treatment from early hormone regulation experiments to modern precision therapies. Key findings include significant advances in prolactinoma and acromegaly treatments, as well as emerging areas for research like receptor modulators and immunotherapy.
A study found that postmenopausal women with low-risk tumors experience a long-term benefit from anti-hormonal treatment of at least 20 years, while younger women do not. The researchers highlight the need for new markers to predict long-term risk and benefit in younger patients.
Researchers at Mass Eye and Ear developed an mRNA-based therapy to prevent scarring and blindness in PVR. The treatment, called RUNX1-Trap, targets a protein that regulates scar tissue formation, showing early promise for treating this eye disease.
The SONIA trial found that delaying and shortening CDK4/6 inhibitor treatment in patients with hormone receptor-positive advanced breast cancer leads to similar survival outcomes while reducing toxicity and cost by €45 million per year. This innovative approach could reduce the burden on healthcare systems worldwide.
Researchers found impaired PD-1 activity can significantly reduce antibody diversity and quality in memory B cells. This may explain the increased rates of infection reported in patients with cancer receiving checkpoint inhibitor therapy.
A cohort study found that nearly half of participants who consumed alcohol at baseline decreased their alcohol use after initiating anti-obesity medication treatment. The medications, such as naltrexone and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), may have properties that lead to reduced cravings for alcohol.
A randomized phase 3 trial found that adding temozolomide to radiation therapy improves long-term survival for adult patients with low-grade gliomas. The 10-year survival rate was 70% with combined treatment, compared to 47% with radiation alone.
Researchers at UCL found that excess brain volume loss with amyloid-targeting immunotherapies is associated with therapy effectiveness, not harm. The 'amyloid-removal-related pseudo-atrophy' or ARPA phenomenon suggests that removal of amyloid plaques may be the cause of observed brain changes.
The new effort aims to rapidly transform academic breakthroughs into life-saving therapies for a range of medical conditions. Autobahn Labs will invest up to $5 million per selected project to support the development of new pharmaceuticals.
Researchers explore adapting agricultural techniques, such as integrated pest management, to treat cancer. By managing cancer as a chronic condition, adaptive therapy aims to overcome treatment resistance and improve patient outcomes.
Researchers found that short-term MHT did not cause long-term cognitive decline in women in early postmenopause. The KEEPS Continuation Study suggests that timing is crucial for the safety of MHT.
A new study by Weill Cornell Medicine scientists reveals that the enzyme EZH2 drives aggressive tumor growth in treatment-resistant prostate cancers. The absence of protein PKCλ/ι enables EZH2's alternative function, promoting cancer progression despite androgen receptor inhibitors.
Researchers at Karolinska Institutet have identified a molecule that can promote mucosal healing through tissue regeneration, potentially treating inflammatory bowel disease and colorectal cancer. The study found that activation of the Liver X receptor suppresses tumor growth in colorectal cancer, offering new therapeutic strategies.
Researchers developed a novel lentivirus-based gene therapy strategy in CD34+ hematopoietic progenitor cells, which showed therapeutic levels of expression of the anti-sickling beta globin protein. Cyclosporin improved transduction efficiency and preserved cell viability.
A novel CAR T-cell therapy targeting p95HER2-expressing cells demonstrates complete and durable antitumor responses in a subset of HER2+ tumors, raising hopes for improved cancer treatment. The therapy also activates immune cells within the tumor microenvironment, showing promising results.
A new finger prick test for Alzheimer's disease has shown strong performance in a European study, measuring biomarkers in blood from superficial vessels. The test could soon be implemented globally, increasing accessibility to Alzheimer's testing without the need for high-sensitivity analyses.
Researchers found that sacubitril-valsartan, a commonly prescribed heart failure medication, can help prevent heart damage related to chemotherapy treatment among high-risk cancer patients. The study highlights the importance of identifying patients at high risk for heart damage and suggests strategies for early intervention.
A study reveals that nearly 137 million US adults are eligible for semaglutide therapy, more than the number eligible for statins. Semaglutide's broad eligibility could lead to increased adoption and treatment options for US adults.
A study found that pharmacists who received feedback about their heart failure patients increased the frequency of their patient interactions and prescribed more medication adjustments. The intervention, which provided educational resources and monthly audit and feedback emails, led to a significant increase in heart failure management.
Researchers found that ablation reduced ICD shocks for ventricular tachycardia and episodes of VT not detected by the ICD. This minimally invasive procedure destroys abnormal heart tissue causing VT, offering a better alternative to long-term medication side effects.
The international SUMMIT trial found tirzepatide lowered the risk of worsening heart failure events and cardiovascular death in obese adults with preserved ejection fraction. Participants experienced improved health status, physical function, and exercise tolerance compared to placebo.
Researchers have created a method to track genetically modified immune cells using PET scans, providing real-time insights into their behavior and persistence in solid tumors. This technology has the potential to inform personalized treatment options and optimize therapy regimens.
Researchers at St. Jude Children's Research Hospital identified a key role for glutamine in red blood cell development and disease. Glutamine metabolism plays a critical role in removing toxic byproducts, such as ammonium, that can accumulate during heme production.
Researchers discovered artemisinin partial resistance in Ugandan children with complicated malaria linked to the Pfkelch13 A675V genetic variation. This finding also highlights concerns over suboptimal treatment efficacy of parenteral artesunate followed by oral artemether/lumefantrine therapy.
Researchers at the University of Nottingham have discovered that GLP-1 receptor agonists may be effective in reducing alcohol consumption. The study suggests that this type of diabetes medication could potentially treat excessive alcohol use and lead to a reduction in alcohol-related deaths.
A recent study from Uppsala University found that genetic variation in cancer cells can enhance the effects of an already approved cancer drug, talazoparib, against liver cancer cells lacking a functional CYP2D6 enzyme. This suggests a potential for more individually tailored and effective cancer therapies.
A comprehensive review recommends computer-assisted cognitive-behavioral therapy (CCBT) and mobile mental health apps as a viable treatment option for depression and anxiety. Effective CCBT programs have been shown to reduce symptoms, while well-developed mobile apps can supplement in-person treatments.
Researchers developed a new AI-powered diagnostic system, FastGlioma, which reveals invisible cancerous tissue in brain tumor surgery. The technique may delay or prevent recurrence of high-grade tumors and improve patient survival.
A new study found that GLP-1 agonists semaglutide and liraglutide were associated with reduced hospitalisations among individuals with alcohol use disorder. The use of these drugs was linked to lower risks of hospitalisation due to alcohol and substance use related causes, as well as physical illnesses.
The C-Path initiative aims to generate drug development solutions that reflect each person's unique experience, leveraging diverse data and innovative technologies like AI and digital health. GEM-PD seeks to address unmet need in Parkinson's disease therapies by focusing on sex and gender differences.
Researchers at McMaster University have identified a potential treatment for Sandhoff and Tay-Sachs diseases, two rare lysosomal storage disorders that cause progressive damage to nerve cells. The FDA-approved drug 4-phenylbutyric acid (4-PBA) showed significant improvements in motor function, lifespan, and healthy motor neurons.
Researchers found semaglutide and liraglutide substantially decrease AUD hospitalization risk compared to approved medications. Clinical trials are needed to confirm these findings and explore their efficacy in treating AUD.
The new hospital will provide patient-centered care with personalized, compassionate treatment and groundbreaking research. Patients will have access to top specialists and pioneering therapies in cancer treatment.
Researchers have developed a practical calculator to predict the risk of developing epilepsy after cerebral venous thrombosis, a rare cause of stroke. The tool is based on factors already available in clinical routine and can help inform treatment decisions or support preventive medication for those at high risk.
A new study found that beta blockers, commonly used to treat heart attack patients with normal pumping function, may lead to increased depression symptoms. Researchers observed more severe depression symptoms in patients who received beta blockers compared to those who did not.
Researchers at Tel Aviv University found that a special protocol of hyperbaric oxygen therapy can improve the condition of PTSD sufferers, reducing typical symptoms such as flashbacks, hypervigilance, and irritability. The study showed improvements in brain connectivity and clinical symptoms, offering new hope for millions of PTSD suff...
Scientists at Max Planck Institute for Intelligent Systems developed a novel method for deploying multiple magnetic miniature robots to navigate through complex networks resembling blood vessels. The system allows for simultaneous treatment of multiple locations, saving critical time and enabling localized care.
Researchers developed a 36-gene predictive score that surpasses conventional methods in predicting tamoxifen treatment resistance. The polygenic score UAB36 has potential as a tool for personalized medicine, helping identify patients at higher risk of poor survival and suggesting alternative treatment strategies.
A collaborative study led by Dr. Julie St-Pierre at the University of Ottawa found that promoting mitochondrial elongation in cancer cells hobbles their ability to metastasize. The research team identified a common signature that could help determine which pathways lead to decreased metastasis.
Dr. Andreazza's work focuses on identifying biomarkers for personalized treatments in metabolic psychiatry, with breakthroughs in brain organoids and mitochondrial transplantation techniques. Her innovative approach aims to revolutionize treatment for both psychiatric and metabolic disorders.
Researchers at UCSD found psilocybin therapy reduces eating disorder psychopathology and improves quality-of-life in patients with anorexia nervosa, but results vary widely among individuals. Genetic variations may influence treatment outcomes.